GlassScriptPhysician profile
Jinal Gangar
NPI 1245618164
$3,675.58
in general payments reported to CMS, 2019-2025
30 companies · $307 in 2025
The $307 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,879 · 2020: $403 · 2021: $447 · 2022: $216 · 2023: $384 · 2024: $40.56 · 2025: $307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $531 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $531.22 |
| Education | $199.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $437.23 | 2019-2023 | Farxiga |
| Pfizer INC. | $388.89 | 2019-2023 | |
| Glaxosmithkline, LLC. | $383.92 | 2019-2023 | Shingrix, Arexvy |
| Esperion Therapeutics, INC. | $227.38 | 2021-2023 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $221.18 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $206.57 | 2019-2023 | Gardasil 9, Vaxneuvance, Rotateq |
| Astellas Pharma US INC | $203.03 | 2019 | |
| Jazz Pharmaceuticals INC. | $199.98 | 2025 | |
| Novo Nordisk INC | $188.23 | 2019-2023 | |
| Lilly USA, LLC | $158.17 | 2019-2024 | Mounjaro, Zepbound |
| Eisai INC. | $136.17 | 2019-2021 | |
| Abbvie INC. | $112.85 | 2021-2022 | |
| Endologix LLC | $106.52 | 2025 | Alto Abdominal Stent Graft System |
| Amgen INC. | $95.77 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $95.61 | 2021-2023 | Rexulti |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $72.03 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $67.98 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $67.55 | 2019-2020 | |
| Exact Sciences Corporation | $58.52 | 2023 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $56.91 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.05 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $27.15 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $25.49 | 2024 | Voquezna |
| Nevro Corp. | $19.67 | 2021 | |
| Mylan Specialty L.P. | $19.54 | 2020 | |
| Scynexis, INC. | $17.42 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $14.36 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.78 | 2019 | |
| Aytu Biopharma, INC. | $13.61 | 2019 | |
| Allergan, INC. | $11.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jinal Gangar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.